RVL Pharmaceuticals plc Quarterly Depreciation, Depletion and Amortization in USD from Q1 2018 to Q1 2023

Taxonomy & unit
us-gaap: USD
Description
The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.
Summary
RVL Pharmaceuticals plc quarterly/annual Depreciation, Depletion and Amortization history and growth rate from Q1 2018 to Q1 2023.
  • RVL Pharmaceuticals plc Depreciation, Depletion and Amortization for the quarter ending March 31, 2023 was $93K, a 4.49% increase year-over-year.
  • RVL Pharmaceuticals plc annual Depreciation, Depletion and Amortization for 2022 was $375K, a 95.4% decline from 2021.
  • RVL Pharmaceuticals plc annual Depreciation, Depletion and Amortization for 2021 was $8.18M, a 61.1% decline from 2020.
  • RVL Pharmaceuticals plc annual Depreciation, Depletion and Amortization for 2020 was $21M, a 63.1% decline from 2019.
Depreciation, Depletion and Amortization, Quarterly (USD)
Depreciation, Depletion and Amortization, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2023 $93K +$4K +4.49% Jan 1, 2023 Mar 31, 2023 10-Q 2023-05-11
Q1 2022 $89K -$3.9M -97.8% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q1 2021 $3.99M -$1.58M -28.3% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-12
Q1 2020 $5.56M -$12.4M -69.1% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-13
Q1 2019 $18M -$2.42M -11.9% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-12
Q1 2018 $20.4M Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-09
* An asterisk sign (*) next to the value indicates that the value is likely invalid.